Strategies for pulmonary delivery of drugs

Deshmukh, Rohitas; Bandyopadhyay, Nabamita; Abed, Sara Nidal; Bandopadhyay, Shantanu; Pal, Yogendra; Deb, Pran Kishore

doi:10.1016/b978-0-12-814487-9.00003-x

Cited by 8 publications

(7 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have been carried out extensively using in vivo, in vitro and mathematical models to study aerosol deposition in the lungs [80]. Thus, the amount of drug reaching the respiratory tract has been shown to be directly proportional to its clinical efficacy [81].…”

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

“…At high speed, large particles cannot follow the path of the airflow in an area implying an important change of direction [60,89]. As a result, particles of large size and high mass (density) strike (colloid) and settle in areas where the airway of the upper respiratory tract branches off [80]. The probability of impact increases with increasing air speed, breathing frequency and particle size [60].…”

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

“…This latter occurs when the gravitational force acting on a particle exceeds the total force of air resistance [60]. Thus, particles in the dispersed phase settle and fall out of the air stream at a constant rate due to gravity or a centrifugal force imposed in these lung regions [60,80]. This mechanism is observed mainly for particles larger than 0.5 μm [64,87,91,92].…”

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

“…The collision of gas molecules with small aerosol particles exerts discrete and non-uniform pressures on the particles surface, resulting in a random Brownian motion [60]. This latter leads to the deposition of the drug and its diffusion into the alveoli [80].…”

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

See 3 more Smart Citations

Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases

Douafer

Andrieu

Brunel

2020

Journal of Controlled Release

View full text Add to dashboard Cite

The rise of antimicrobial resistance has created an urgent need for the development of new methods for antibiotics delivery to patients with pulmonary infections in order to mainly increase the effectiveness of the drugs administration, to minimize the risk of emergence of resistant strains, and to prevent patients reinfection. Since bacterial resistance is often related to antibiotic concentration, their pulmonary administration could eradicate strains resistant to the same drug at the concentration achieved through the systemic circulation. Pulmonary administration offers several advantages; it directly targets the site of the infection which allows the inhaled dose of the drug to be reduced compared to that administered orally or parenterally while keeping the same local effect. The review article is made with an objective to compile information about various existing modern technologies developed to provide greater patient compliance and reduce the undesirable side effect of the drugs. In conclusion, aerosol antibiotic delivery appears as one of the best technologies for the treatment of pulmonary infectious diseases and able to limit the systemic adverse effects related to the high drug dose and to make life easier for the patients.

show abstract

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

Section: Mechanism and Factors Influencing Particles Depositionmentioning

confidence: 99%

See 2 more Smart Citations

Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases

Douafer

Andrieu

Brunel

2020

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Pulmonary drug delivery is an attractive route for drugs used in both local and systemic treatment [ 1 , 2 , 3 , 4 ]. Many challenges exist in the manufacturing stages of inhalations for pulmonary drug delivery systems [ 5 , 6 , 7 , 8 , 9 ]. Nevertheless, the proven efficiency of this route for many drugs pushes toward finding practical solutions.…”

Section: Introductionmentioning

confidence: 99%

Preparation of Hybrid Alginate-Chitosan Aerogel as Potential Carriers for Pulmonary Drug Delivery

2020

View full text Add to dashboard Cite

This study aims to prepare hybrid chitosan-alginate aerogel microparticles without using additional ionic crosslinker as a possible pulmonary drug delivery system. The microparticles were prepared using the emulsion gelation method. The effect of the mixing order of the biopolymer within the emulsion and the surfactant used on final particle properties were investigated. Physicochemical characterizations were performed to evaluate particle size, density, morphology, surface area, surface charge, and the crystallinity of the preparation. The developed preparation was evaluated for its acute toxicity in adult male Sprague-Dawley rats. Measurements of zeta potential suggest that the surface charge depends mainly on the surfactant type while the order of biopolymer mixing has less impact on the surface charge. Chitosan amphiphilic properties changed the hydrophilic-lipophilic balance (HLB) of the emulsifying agents. The specific surface area of the prepared microparticles was in the range of (29.36–86.20) m2/g with a mesoporous pore size of (12.48–13.38) nm and pore volume of (0.09–0.29) cm3/g. The calculated aerodynamic diameter of the prepared particles was in the range of (0.17–2.29 µm). Toxicity studies showed that alginate-chitosan carrier developed herein caused mild lung inflammation with some renal and hepatic toxicities.

show abstract